-
公开(公告)号：JP2002047298A
公开(公告)日：2002-02-12
申请号：JP2000208258
申请日：2000-07-10
Applicant: ACADEMIA SINICA
Inventor： SHUI-TEIN CHEN , IN-TA U , CHUN-MIN FUAN
Abstract: PROBLEM TO BE SOLVED: To solve the problem of toxic side action of various cytotoxic anticancer agent lacking a selective drug transfer system and to improve the transfer efficiency of drug. SOLUTION: The new system for the transfer of an anti-cancer agent to a cancer cell is produced by using a new cancer treating compound expressed by general formula paclitaxel (or PEG-DOPE)-O-R-NH-R' [R is a dicarboxylic acid residue; and R' is somatostatin analog]. The compound can be synthesized by a solid phase process.
-
公开(公告)号：US20160076039A1
公开(公告)日：2016-03-17
申请号：US14873275
申请日：2015-10-02
Applicant: Academia Sinica
Inventor： SHUI-TEIN CHEN , TING-FANG LO , WEI-CHUNG TSAI
IPC: C12N15/113 , A61K31/4375
CPC classification number: C12N15/1137 , A61K31/4375 , A61K31/7105 , C12N15/113 , C12N2310/141 , C12N2320/30 , C12N2320/32
Abstract: The present invention relates to a pharmaceutical composition for treating liver diseases, comprising a miRNA mimic containing a single strand RNA molecule of hsa-miR-21-3p (SEQ ID No: 35). The miRNA mimic of the present invention can be used to treat liver diseases through regulating the expression of methionine adenosyltransferase 2A and 2B (MAT2A and MAT2B), acetyl-CoA carboxylase 1 and 2 (ACACA and ACACB), diglyceride acyltransferase 2 (DGAT2), and so on. In addition, the present invention also relates to a method for reducing the expression of the above-mentioned enzymes.
-
公开(公告)号：US20150225719A1
公开(公告)日：2015-08-13
申请号：US14496280
申请日：2014-09-25
Applicant: Academia Sinica
Inventor： SHUI-TEIN CHEN , TING-FANG LO , WEI-CHUNG TSAI
IPC: C12N15/113 , A61K31/4375
CPC classification number: C12N15/1137 , A61K31/4375 , A61K31/7105 , C12N15/113 , C12N2310/141 , C12N2320/30 , C12N2320/32
Abstract: The present invention relates to a pharmaceutical composition for treating liver diseases, comprising a miRNA mimic containing a single strand RNA molecule of hsa-miR-21-3p (SEQ ID No: 35). The miRNA mimic of the present invention can be used to treat liver diseases through regulating the expression of methionine adenosyltransferase 2A and 2B (MAT2A and MAT2B), acetyl-CoA carboxylase 1 and 2 (ACACA and ACACB), diglyceride acyltransferase 2 (DGAT2), and so on. In addition, the present invention also relates to a method for reducing the expression of the above-mentioned enzymes.
Abstract translation: 本发明涉及用于治疗肝脏疾病的药物组合物，其包含含有hsa-miR-21-3p（SEQ ID No：35）的单链RNA分子的miRNA模拟物。 本发明的miRNA模拟物可用于通过调节甲硫氨酸腺苷转移酶2A和2B（MAT2A和MAT2B），乙酰辅酶A羧化酶1和2（ACACA和ACACB），甘油二酯酰基转移酶2（DGAT2）的表达来治疗肝脏疾病， 等等。 此外，本发明还涉及降低上述酶表达的方法。
-
公开(公告)号：US20160109452A1
公开(公告)日：2016-04-21
申请号：US14538888
申请日：2014-11-12
Applicant: Academia Sinica , National Taiwan University
Inventor： SHUI-TEIN CHEN , CHONG-JEN YU , POTPROMMANEE LADDAWAN , HAOU-TZONG MA
IPC: G01N33/574 , C07K14/47
CPC classification number: G01N33/57423 , C07K14/4706 , G01N2333/4706 , G01N2800/52
Abstract: The present invention relates to a lung cancer biomarker for diagnosing early stage lung cancers or predicting prognosis of lung cancers, which comprises a GM2AP protein. The present invention also relates to a method for diagnosing early stage lung cancers or predicting prognosis of lung cancers in vitro by detection of the biomarker.
Abstract translation: 本发明涉及用于诊断早期肺癌或预测肺癌预后的肺癌生物标志物，其包含GM2AP蛋白。 本发明还涉及通过检测生物标志物来诊断早期肺癌或通过体外预测肺癌预后的方法。
-
-
-
Search Results
4
records
(took 0.019 seconds)
